Myocardial performance index and biochemical markers for early detection of doxorubicin-induced cardiotoxicity in children with acute lymphoblastic leukaemia

International Journal of Clinical Oncology

Volumn 18, Issue 5, 2013, Pages 927-933

  Ruggiero, Antonio ^a   De Rosa, Gabriella ^b   Rizzo, Daniela ^a   Leo, Andrea ^b   Maurizi, Palma ^a   De Nisco, Alessia ^b   Vendittelli, Francesca ^a   Zuppi, Cecilia ^a   Mordente, Alvaro ^a   Riccardi, Riccardo ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Acute lymphoblastic leukaemia; Cardiotoxicity; Children; Doxorubicin; Myocardial performance index

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; DOXORUBICIN; TROPONIN T;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RESPONSE; CHILD; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOXORUBICIN INDUCED CARDIOTOXICITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED DISEASE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; FRACTIONAL SHORTENING; HEART EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE EJECTION TIME; HUMAN; HUMAN CELL; ISOVOLUMIC CONTRACTION TIME; ISOVOLUMIC RELAXION TIME; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MALE; MULTIPLE CYCLE TREATMENT; MYOCARDIAL PERFORMANCE INDEX; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SCHOOL CHILD; TREATMENT DURATION;

CARDIOTOXINS; CHILD; CHILD, PRESCHOOL; DOXORUBICIN; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; FEMALE; HEART; HEART FAILURE; HUMANS; INFANT; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; TROPONIN C;

EID: 84886091760     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-012-0458-9     Document Type: Article

References (32)

1. Rather M, Carlsen NL, Oxhøj H (2007) Late cardiac effects of anthracycline containing therapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 48:663-667
2. Steinherz LJ, Steinherz PG, Tan CT et al (1991) Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266:1672-1677
3. van Dalen EC, van der Pal HJ, Kok WE et al (2006) Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. Eur J Cancer 42:3191-3198
4. Pai VB, Nahata MC (2000) Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 22:263-302
5. Eidem BW, Sapp BG, Suarez CR et al (2001) Usefulness of the myocardial performance index for early detection of anthracycline-induced cardiotoxicity in children. Am J Cardiol 87:1120-1122
6. Belham M, Kruger A, Pritchard C (2006) The Tei index identifies a differential effect on left and right ventricular function with low-dose anthracycline chemotherapy. J Am Soc Echocardiogr 19:206-210
7. Ishii M, Tsutsumi T, Himeno W et al (2000) Sequential evaluation of left ventricular myocardial performance in children after anthracycline therapy. Am J Cardiol 86:1279-1281
8. Sato T, Harada K, Tamura M et al (2001) Cardiorespiratory exercise capacity and its relation to a new Doppler index in children previously treated with anthracycline. J Am Soc Echocardiogr 14:256-263
9. Ocal B, Oguz D, Karademir S et al (2002) Myocardial performance index combining systolic and diastolic myocardial performance in doxorubicin-treated patients and its correlation to conventional echo/Doppler indices. Pediatr Cardiol 23:522-527
10. Dodos F, Halbsguth T, Erdmann E et al (2008) Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol 97:318-326
11. Herman EH, Zhang J, Lipshultz SE et al (1999) Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 17:2237-2243
12. Lipshultz SE, Rifai N, Dalton VM et al (2004) The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 351:145-153
13. Lipshultz SE, Rifai N, Sallan SE et al (1997) Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 96:2641-2648
14. Mavinkurve-Groothuis AM, Kapusta L, Nir A et al (2008) The role of biomarkers in the early detection of anthracycline-induced cardiotoxicity in children: a review of the literature. Pediatr Hematol Oncol 25:655-664
15. Lipshultz SE, Scully RE, Lipsitz SR et al (2010) Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 11:950-961
16. Albers S, Mir TS, Haddad M et al (2006) N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability. Clin Chem Lab Med 44:80-85
17. Lang RM, Bierig M, Devereux RB et al (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440-1463
18. Ocal B, Oguz D, Karademir S et al (2003) Myocardial performance index combining systolic and diastolic myocardial performance in doxorubicin-treated patients and its correlation to conventional echo/Doppler indices. Pediatr Cardiol 23:522-527
19. Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869-2879
20. Wojtacki J, Lewicka-Nowak E, LeÅniewski-Kmak K (2000) Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention - review of the literature. Med Sci Monit 6:411-420
21. Ruggiero A, Ridola V, Puma N et al (2008) Anthracycline cardiotoxicity in childhood. Pediatr Hematol Oncol 25:261-281
22. Doroshow JH, Locker GY, Myers CE (1980) Enzymatic defenses of the mouse heart against reactive oxygen metabolites. J Clin Invest 65:128-135
23. Rossi F, Filippelli W, Russo S et al (1994) Cardiotoxicity of doxorubicin: effects of drugs inhibiting the release of vasoactive substances. Pharmacol Toxicol 75:99-107
24. Goormaghtigh E, Huart P, Praet M et al (1990) Structure of the doxorubicin-cardiolipin complex role in mitochondrial toxicity. Biophys Chem 35:247-257
25. Huber SA (1990) Doxorubicin-induced alterations in cultured myocardial cells stimulate cytolytic T lymphocyte responses. Am J Pathol 137:449-456
26. Yeh ET, Tong AT, Lenihan DJ et al (2004) Cardiovascular complication of cancer therapy: diagnosis, pathogenesis and management. Circulation 109:3122-3131
27. Kurz K, Voelker R, Zdunek D et al (2007) Effect of stress-induced reversible ischemia on serum concentrations of ischemia-modified albumin, natriuretic peptides and placental growth factor. Clin Res Cardiol 96:152-159
28. Weber M, Kleine C, Keil E et al (2006) Release pattern of N-terminal pro B-type natriuretic peptide (NT-proBNP) in acute coronary syndromes. Clin Res Cardiol 95:270-280
29. Daugaard G, Lassen U, Bie P et al (2005) Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail 7:87-93
30. Suzuki T, Hayashi D, Yamazaki T et al (1998) Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 136:362-363
31. Herman EH, Zhang J, Lipshultz SE et al (1999) Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 17:2237-2243
32. Fink FM, Genser N, Fink C et al (1995) Cardiac troponin T and creatine kinase MB mass concentrations in children receiving anthracycline chemotherapy. Med Pediatr Oncol 25:185-189